AlzeCure Publishes its Interim Report for January - March 2025
STOCKHOLM, SE / ACCESS Newswire / May 5, 2025 /AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March 2025 is now available on the company 's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"The first quarter of 2025 was yet another active and eventful quarter for AlzeCure Pharma. In February 2025, we received a grant of EUR 2.5 million from the European Innovation Council (EIC), with the possibility of additional funding through the EIC fund. We are very proud and honored to receive this prestigious grant, which is both a significant financial contribution to the company and an acknowledgment of the groundbreaking potential of ACD856. During the quarter, we also published and presented new positive preclinical findings from our clinical Alzheimer 's project NeuroRestore ACD856 at the world-leading Alzheimer 's and Parkinson 's Diseases (AD/PD) conference. We also published new data in our other Alzheimer 's project, Alzstatin, which showed a clear plaque-reducing effect, among other findings. With these positive results, we demonstrate that AlzeCure continues to deliver."
Martin Jönsson, CEO
Financial information for January - March, 2025
Figures in parentheses refer to the corresponding period of the previous year.
Net sale sales during the period totaled SEK 0 thousand (0).
Earnings for the period totaled SEK -10,108 thousand (-9,804).
Earnings per share, basic, totaled SEK -0.11 (-0.16).
Cash flow from operating activities totaled SEK -10,679 thousand (SEK -10,063).
Total assets at the end of the period amounted to SEK 24,718 thousand (22,688).
Cash and cash equivalents at the end of the period totaled SEK 20,819 thousand (19,037).
Significant events during the period January - March, 2025
The company announces on February 17, 2025, that it has been awarded an EU grant for a Phase II clinical trial of NeuroRestore ACD856 for Alzheimer 's disease.
In February, the company publishes a new scientific article demonstrating the unique mechanism of action behind Alzstatin, which is being developed for Alzheimer 's disease.
On April 9, the company announces that its Annual General Meeting will convene on May 14, 2025.
Significant events after the end of the period
In early April, the company presents new preclinical data for the lead drug candidate NeuroRestore ACD856 at the international Alzheimer 's and Parkinson 's Disease (AD/PD) conference in Vienna.
The full report is attached as PDF and is available on the company 's website: www.alzecurepharma.com/en/section/investors/financial-reports/
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure ®is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer 's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore ® , Alzstatin ® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer 's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson 's disease and is being prepared for phase 2. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer 's disease. Painless is the company 's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain with positive phase 2 results, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB is the company 's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Attachments
SOURCE: AlzeCure Pharma
View the original press release on ACCESS Newswire
© 2025 ACCESS Newswire. All Rights Reserved.
